New hope for tough colon cancers: fruquintinib trial targets unmet need
NCT ID NCT07510932
First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a drug called fruquintinib in 88 adults with advanced colon cancer that no longer responds to standard chemotherapies. The goal is to see if adding supportive care to manage side effects can help patients stay on treatment longer and slow cancer growth. It is a phase 2 trial in South Korea for people who have run out of effective options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.